Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin consolidation after first-line R-CVP in PET-positive partial remission follicular lymphoma
NL-OMON33142Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by Vrije University Medical Center. Primary endpoint: Conversion rate from partial remission to complete remission. Started Nov 2009; status: active, not recruiting.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON33142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33142.